CN1194832A - Antiparasitic medicine containing avermectin/ivermectin for animals - Google Patents
Antiparasitic medicine containing avermectin/ivermectin for animals Download PDFInfo
- Publication number
- CN1194832A CN1194832A CN97103659A CN97103659A CN1194832A CN 1194832 A CN1194832 A CN 1194832A CN 97103659 A CN97103659 A CN 97103659A CN 97103659 A CN97103659 A CN 97103659A CN 1194832 A CN1194832 A CN 1194832A
- Authority
- CN
- China
- Prior art keywords
- agent
- avm
- ivm
- antiseptic
- emulsion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002141 anti-parasite Effects 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title claims abstract description 11
- 239000003096 antiparasitic agent Substances 0.000 title claims abstract description 8
- 241001465754 Metazoa Species 0.000 title claims description 8
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 title abstract description 21
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 title abstract description 21
- 229960002418 ivermectin Drugs 0.000 title abstract description 21
- 239000005660 Abamectin Substances 0.000 title abstract description 7
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 title abstract description 6
- 239000000839 emulsion Substances 0.000 claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960002669 albendazole Drugs 0.000 claims abstract description 10
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims abstract description 5
- 239000006071 cream Substances 0.000 claims abstract description 5
- 229960001614 levamisole Drugs 0.000 claims abstract description 5
- 239000000375 suspending agent Substances 0.000 claims description 29
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 24
- 239000002674 ointment Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 230000002421 anti-septic effect Effects 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000003995 emulsifying agent Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 8
- 239000004299 sodium benzoate Substances 0.000 claims description 8
- 235000010234 sodium benzoate Nutrition 0.000 claims description 8
- 229920001285 xanthan gum Polymers 0.000 claims description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000080 wetting agent Substances 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 5
- 235000019441 ethanol Nutrition 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 3
- 230000000507 anthelmentic effect Effects 0.000 claims description 3
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- 229960004025 sodium salicylate Drugs 0.000 claims description 2
- JHJUUEHSAZXEEO-UHFFFAOYSA-M sodium;4-dodecylbenzenesulfonate Chemical compound [Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1 JHJUUEHSAZXEEO-UHFFFAOYSA-M 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 239000010775 animal oil Substances 0.000 claims 1
- -1 antiseptic Substances 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 2
- AZSNMRSAGSSBNP-XPNPUAGNSA-N 22,23-dihydroavermectin B1a Chemical compound C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 AZSNMRSAGSSBNP-XPNPUAGNSA-N 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 229960004063 propylene glycol Drugs 0.000 description 11
- 239000007788 liquid Substances 0.000 description 8
- 239000005645 nematicide Substances 0.000 description 8
- 229920000136 polysorbate Polymers 0.000 description 7
- 239000000843 powder Substances 0.000 description 6
- 239000004576 sand Substances 0.000 description 6
- 239000003292 glue Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000273 veterinary drug Substances 0.000 description 4
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 2
- 239000000921 anthelmintic agent Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000000749 insecticidal effect Effects 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 229930192734 Avilamycin Natural products 0.000 description 1
- 239000004190 Avilamycin Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000239183 Filaria Species 0.000 description 1
- 241001137878 Moniezia Species 0.000 description 1
- 241001137882 Nematodirus Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241001468227 Streptomyces avermitilis Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- XIRGHRXBGGPPKY-OTPQUNEMSA-N [(2r,3s,4r,6s)-6-[(2'r,3's,3ar,4r,4'r,6s,7ar)-6-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4s,5s,6s)-6-[(2r,3as,3'ar,6'r,7r,7's,7ar,7'ar)-7'-acetyl-7'-hydroxy-6'-methyl-7-(2-methylpropanoyloxy)spiro[4,6,7,7a-tetrahydro-3ah-[1,3]dioxolo[4,5-c]pyran-2,4'-6,7a-dihydro-3ah- Chemical compound O([C@H]1[C@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@H](O)CC2(O[C@]3(C)C[C@@H](O[C@H](C)[C@H]3O2)O[C@H]2[C@@H](OC)[C@@H](C)O[C@H]([C@@H]2O)O[C@H]2[C@H](O)[C@H](OC)[C@H](OC3[C@@H]([C@@H]4O[C@]5(O[C@H]4CO3)[C@@H]3OCO[C@H]3[C@@](O)([C@@H](C)O5)C(C)=O)OC(=O)C(C)C)O[C@@H]2COC)O[C@@H]1C)C(=O)C1=C(C)C(Cl)=C(O)C(Cl)=C1OC XIRGHRXBGGPPKY-OTPQUNEMSA-N 0.000 description 1
- 229950008167 abamectin Drugs 0.000 description 1
- 229960005185 avilamycin Drugs 0.000 description 1
- 235000019379 avilamycin Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 244000079386 endoparasite Species 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A veterinary antiparasitic containing avermectin (AVM) or ivermectin (IVM) (0.05-10%) features that it is a compound veterinary medicine of the colloidal suspension, emulsion or cream containing AVM/IVM, levamisole and Albendazole, and features low cost, simple preparing process and high effect.
Description
The invention belongs to anti-parasite medicine for animal use, or rather, the present invention is a kind of avilamycin (Avermectin B
1, be called for short AVM) and veterinary antiparasitic colloidal suspending agent, floating agent and the ointment of or derivatives thereof Ivermectin HCL (Ivermectin is called for short IVM).
The eighties U.S. MERCK company successfully is developed to anti-parasite medicine for animal use with AVM or IVM, but the dosage form that powder, injection, capsule and liniment are all arranged at present, these dosage forms all exist certain shortcoming, as in the powder production process dust pollution being arranged, influence operator ' s health, the liniment large usage quantity, powder, glue are assisted, injection medication inconvenience.
Purpose of the present invention is exactly some shortcomings that overcome prior art, provides a kind of production cost low, colloidal suspending agent, Emulsion and the ointment of the veterinary antiparasitic that contains IVM or AVM that drug effect is high.
Colloidal suspending agent of the present invention is made of AVM, wetting agent, dispersion suspending agent, antifreezing agent, antiseptic, disperse medium, its constituent content (is 100% in colloidal suspending agent weight): IVM or AVM 0.5-10%, wetting agent 0.2-10%, disperse suspending agent 0.2-30%, antifreezing agent 5-15%, antiseptic 0.1-1%, all the other are disperse medium.
The preparation method of described colloidal suspending agent adopts common technology of preparing to be about to AVM or IVM mixes with wetting agent, disperse medium, with the colloid mill homogenize levigate to 20～80 microns again through sand mill levigate to 0.25 micron after, add and disperse suspending agent, antifreezing agent, antiseptic, homogenizing with high speed shear emulsifying dispersion machine promptly gets colloidal suspending agent.
The composition of Emulsion of the present invention and content (weight in Emulsion is 100%): AVM or IVM0.05～10%, organic solvent 2～80%, emulsifying agent 1～30%, viscosifier 0.2～10%, antifreezing agent 5～10%, antiseptic 0.1～1%, all the other are water.
The preparation method of described Emulsion adopts common technology of preparing, is about to AVM or IVM organic solvent dissolution, adds emulsifying agent, and mixing adds stabilizing agent, antifreezing agent, antiseptic and water, and homogenizing with the high speed shear dispersion machine promptly obtains Emulsion.
The composition of ointment of the present invention and content (is 100% in ointment weight): AVM or IVM 0.05～10%, organic solvent 2～80%, emulsifying agent 1～30%, viscosifier 0.5～30%, antifreezing agent 5～15%, antiseptic 0.1～1%, all the other are water.
Described ointment preparation method is identical with Emulsion, just adds more viscosifier and makes formation be difficult to mobile pasty state or emulsifiable paste.
AVM of the present invention is the metabolite of A Foman streptomycete (Streptomyces avermitilis), is A by eight structures
1a, A
1b, A
2a, A
2b, B
1a, B
1b, B
2a, B
2b, homologue form B wherein
1aThe component insecticidal activity is the highest, and insecticidal spectrum is the widest, but B
1bAnd B
1a, structure very close, be difficult to separate, thus the mixture of the two normally, abbreviation AVM.Described IVM (Ivermectin) is the derivant William C.Campbell of AVM, " Ivermectin ana Abamectin ", Springer-verlag New York Inc.1989, P1～23.
Described AVM or IVM also can be made into oily liquid and replace the crystallization product (or claim former medicine) of purity at 90% left and right sides AVM or IVM.The preparation method of oily liquid: produce with strain fermented through 7～9 days filter mycelium, mycelium with acetone, ethanol or other organic solvent lixiviate, filtration, is reclaimed lixiviating solution, after decolouring and removing toxic substance, be evaporated to the ointment shape, this paste mixture contains Avermectin A
13～10%, A
28～25%, B
1, 6～25%, B
23～10%, lipid 10～30%, water 5～10%.
Described wetting agent comprises tween 80, sodium lauryl sulphate, dodecylbenzene sodium sulfonate; Described dispersion suspending agent comprises xanthan gum, arabic gum, methylcellulose, carboxymethyl cellulose; Described antifreezing agent comprises ethylene glycol, propylene glycol; Described emulsifying agent comprises tween 80, OP-10, OP-21; Described antiseptic comprises that sodium benzoate, salicylic acid are received, benzyl alcohol; Described organic solvent comprises ethyl acetate, acetone, ethanol; Described disperse medium comprises water, vegetable and animals oils.
Can add other known anthelmintic drug in single agent of above-mentioned colloidal suspending agent, Emulsion and ointment and make the compound recipe colloidal suspending agent, compound recipe Emulsion and compound cream agent.Described other anthelmintic drug comprises levamisole, Albendazole, and addition is 1～20% of a compound preparation weight, its adding mode: mix with other component in the single agent of preparation, perhaps join in Manufactured single agent, then mix homogeneously.
Colloidal suspending agent of the present invention, Emulsion, ointment or its compound preparation can be used for cattle, the sheep anthelmintic comprises nematicide in the body, parasites such as external demodicid mite, Ticks, louse, fly larvae.When using colloidal suspending agent, Emulsion or ointment compound preparation, behind the dilute with water, by per kilogram of body weight 0.2 milligram of calculating of AVM (or IVM), per os gavages.
AVM of containing proposed by the invention or IVM anti-posting for animals used the worm preparation, overcome the shortcoming of existing preparation, owing to few usefulness or without organic solvent, production cost is reduced, and production technology is simple, no dust pollution in the production process, pack easyly, it is also extremely convenient to use, and effect is also relatively good.
Further describe characteristics of the present invention with example below:
Embodiment 1
This example is the colloidal suspending agent that preparation contains AVM 0.1%.
The former medicine (purity 90%) of 0.55KgAVM is milled to below 300 microns, mix with 1kg sodium lauryl sulphate, distilled water 2kg, with colloid mill levigate during to 20～80 microns the reuse sand mill be ground to 0.2～5 micron, add 1% cmc soln and 5% propylene glycol, 1% sodium benzoate to cumulative volume is 500 liters, promptly gets required colloidal suspending agent after homogenizing.
Present embodiment 2
This example is to contain 0.2% colloidal suspending agent with the preparation of the oily liquid of AVM.
Get AVM content and be 10% oily liquid 2kg, adding 4 liters of tween 80s homogenizes with high shearing mixing emulsor under 50 ℃, add 1, add 0.3% xanthan glue to 100 liter after 10 liters of mixing of 2-propylene glycol, being ground to solid particle in sand mill is to get final product below 0.2 micron.
Embodiment 3
This example is the colloidal suspending agent that preparation contains AVM 10%.
The former drug mill of 55kgAVM (purity 90%) is broken to below 300 microns, with 40kg tween 080, distilled water 100kg mixes, be ground to fineness with sand mill during to the 20-80 micron left and right sides and reach the 0.2-5 micron with the colloid mill homogenize is levigate, add 75kg 1,2 propylene glycol, the 0.5kg sodium benzoate adds 10% carboxymethyl cellulose liquid to 500 liter then.
Embodiment 4
This example is the Emulsion that preparation contains 0.2%AVM.
With purity for 90%AVM 1.1Kg with 10 liters of acetone solutions after, add 20 liters of tween 80s, high speed shear is mixed to and homogenizes, add stabilizing solution again and (contain methylcellulose 8%, 1,2-propylene glycol 15%, benzyl alcohol 1%, all the other are water) to 500 liters, homogenizing promptly gets Emulsion.
Embodiment 5
This example is the Emulsion that preparation contains 10%AVM.
Preparation process is with example 3.50 liters of each constituent content: AVM (content 90%) 11Kg ethanol, 30 liters of tween 80s, to 100 liters, homogenizing promptly gets Emulsion to add stabilizing solution (contain xanthan gum 0.2%, 1,2 one propylene glycol 5%, sodium benzoate 0.2%, all the other are water).
Embodiment 6
This example is the ointment that preparation contains 0.2%AVM.
The AVM1.1kg of purity 90% is added OP-1010 after with 10 liters of acetic acid ethyl dissolutions rise and homogenize, add 1,75 liters of 2-propylene glycol, sodium salicylate 1kg, add 1% Arabic glue to 500 liter then, promptly get required ointment through homogenizing with mulser.
Embodiment 7
This example is that preparation contains the 10%IVM ointment.
Preparation process is with example 5.Component utilized content: 11kg purity is 90% IVM, 60 liters of acetone, 20 liters of tween 80s, 5 liter 1,2-propylene glycol, the back that homogenizes add viscosifier (contain xanthan gum 0.9%, sodium benzoate 0.2%, all the other are water) and promptly get ointment through homogenizing again at last to 100 liters.
Embodiment 8
This example is the compound recipe colloidal suspending agent that preparation contains the 0.2%AVM-6% Albendazole.
Get the AVM 0.22kg of purity 90%, add Albendazole 6kg, 1,5 liters of 2-propylene glycol, sodium benzoate 1kg, tween 80 grind in sand mill for 2 liters, levigate 0.15% the xanthan gum solution to 100 liter of adding during to 0.2～5 micron, and further being ground to homogenizes gets final product.
Embodiment 9
This example is the compound cream agent that preparation contains the 5%IVM-18% levamisole.
The IVM5.5Kg that gets purity 90% is behind 10 liters of dissolve with ethanols, add 5 liters of tween 80s, mixing adds 18kg levamisole, 1 again, be ground to 0.2～4 micron of solid phase particles after 5 liters of mixing of 2 one propylene glycol, add 55.5 liters of 0.6% xanthan glues, 1 liter of 10% sodium benzoate liquid then, be trimmed to through stirring and promptly get compound recipe Emulsion after homogenizing.
Embodiment 10
This real side is the compound cream agent that contains the 5%AVM-18% Albendazole with the preparation of AVM oily liquid.
Get AVM content and be 25% oily liquid 20kg, add 18kg Albendazole, 20 liters of tween 80s, 5 liter 1,2 one propylene glycol, being ground to solid phase particles with sand mill is 0.2～2 micron, add 0.8% xanthan glue to 100 liter, further be ground to homogeneity and promptly get required product.
Embodiment 11
This example is preparation of the present invention and contains the AVM powder that capsule relatively.The results are shown in Table 1 and table 2.
The various dosage forms of table one AVM are to all kinds of nematicide worm's ovums of sheep (larva) slip comparison sheet
* the AVM injection is No. 23 veterinary drug book of the new veterinary drug card word of pesticide portion of the People's Republic of China (PRC) (94); * VM powder is No. 24 new veterinary drug certificate of the new veterinary drug card word of pesticide portion of the People's Republic of China (PRC) (94); * * AVM capsule is self-control, and prescription: AVM0.2%, all the other are CaCO
3
| Dosage form | Dosage (mg/kg) | Worm's ovum (larva) slip |
| Hair circle Ovshinsky thin neck net tail former strongylid nematicide nematicide nematicide (children) larva (children) | ||
| Example 2 colloidal suspending agent examples 4 Emulsion examples 6 unguentum 0.2%AVM injection * AVM powder * * AVM capsule * * * | ????0.2 ????0.2 ????0.2 ????0.2 ????0.2 ????0.2 | ??100??98.7???100????100????95.0 ??100??98.5???100????100????93.5 ??100??98.5???100????100????93.7 ??100??98.3???100????100????93.5 ??98.5?97.7???100????98.2???90.3 ??97.6?97.2???100????98.0???89.5 |
Table two: example 8 compound recipe colloidal suspending agents and the agent of AVM Albendazole list are to sheep endoparasite deworming rates comparison sheet
| Project | Multiple agent | The agent of Albendazole list | The single agent of AVM |
| AVM (mg/kg) Albendazole (mg/kg) | ????0.2 ????6 | One 6 | 0.2 one |
| Trichostrongyle oersted nematicide Marshall nematicide nematodirus esophageal orifice nematicide net filaria | ????100 ????100 ????98.7 ????100 ????100 ????99.2 | ????98.3 ????97.6 ????98.0 ????100 ????97.2 ????98.5 | ??98.7 ??99.2 ??98.3 ??100 ??98.0 ??99.2 |
| Moniezia (adult) | ????100 | ????100 | ??0 |
| No vitellarium cestode | ????100 | ????97.3 | ??0 |
Claims (6)
1, a kind of anti-parasite medicine for animal use that contains AVW/IVM is characterized in that being prepared into the colloidal suspending agent, Emulsion and the ointment that contain AVM/IVM0.05～10%.
2, according to the described antiparasitic of claim 1, it is characterized in that colloidal suspending agent is by AVM/IVM and wetting agent, disperse suspending agent, antifreezing agent, antiseptic, disperse medium to mix, it forms content (is 100% in colloidal suspending agent): AVM/IVM 0.05～10%, wetting agent 0.2-10% disperses suspending agent 0.2-30%, antifreezing agent 5-15%, antiseptic 0.1～1%, all the other are disperse medium.
3, according to the described antiparasitic of claim 1, it is characterized in that Emulsion and organic solvent, emulsifying agent, viscosifier, antifreezing agent, antiseptic, water mix, it forms content (is 100% in Emulsion): AVM/IVM 0.05～10%, organic solvent 2～80%, emulsifying agent 1～30%, viscosifier 0.2～10%, antifreezing agent 5～10%, antiseptic 0.1～1%, all the other are water.
4, according to the described antiparasitic of claim 1, it is characterized in that ointment is to be mixed by AVM/IVM and organic solvent, emulsifying agent, viscosifier, antifreezing agent, antiseptic and water, it forms content (is 100% in ointment): AVM/IVM 0.05～10%, organic solvent 2～80%, emulsifying agent 1～30%, viscosifier 0.5～30%, antifreezing agent 5～15%, antiseptic 0.1～1%, all the other are water.
5,, it is characterized in that described wetting agent comprises tween 80, sodium lauryl sulphate, dodecylbenzene sodium sulfonate according to the described antiparasitic of claim 2 to 4; Described dispersion suspending agent comprises xanthan gum, arabic gum, methylcellulose, carboxymethyl cellulose; Described antifreezing agent comprises ethylene glycol, propylene glycol, glycerol; Described emulsifying agent comprises tween 80, OP-10, OP-21; Described antiseptic comprises sodium benzoate, sodium salicylate, benzyl alcohol; Described organic solvent comprises ethanol, acetone, ethyl acetate; Described disperse medium comprises water, animal oil, vegetable oil.
6, a kind of complex anti-parasite medicine for animal use that contains AVM/IVM, it is characterized in that the colloidal suspending agent of claim 1 to the described AVM/IVM of containing of claim 4, be mixed in single agent of Emulsion, ointment and comprise the anthelmintic of levamisole, Albendazole, make compound recipe colloidal suspending agent, compound recipe Emulsion, compound cream agent, the addition of described anthelmintic is 1～20% of a compound preparation weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97103659A CN1069032C (en) | 1997-03-27 | 1997-03-27 | Antiparasitic medicine containing avermectin/ivermectin for animals |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97103659A CN1069032C (en) | 1997-03-27 | 1997-03-27 | Antiparasitic medicine containing avermectin/ivermectin for animals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1194832A true CN1194832A (en) | 1998-10-07 |
| CN1069032C CN1069032C (en) | 2001-08-01 |
Family
ID=5166806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97103659A Expired - Fee Related CN1069032C (en) | 1997-03-27 | 1997-03-27 | Antiparasitic medicine containing avermectin/ivermectin for animals |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1069032C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000074489A1 (en) * | 1999-06-04 | 2000-12-14 | Nufarm Limited | Stable biocidal compositions |
| CN1069033C (en) * | 1998-11-13 | 2001-08-01 | 王玉万 | Anti-parasite oral spray containing evericin and ivermectin for sheep |
| WO2004043445A1 (en) * | 2002-11-11 | 2004-05-27 | Schering-Plough Ltd. | Topical parasiticide formulations and methods of treatment |
| WO2009060063A1 (en) * | 2007-11-09 | 2009-05-14 | Intervet International B.V. | Anthelmintic combination |
| CN101002560B (en) * | 2006-01-17 | 2010-08-18 | 上海农乐生物制品股份有限公司 | Aqueous emulsion containing methyl amino abamectin benzoate, and its preparing method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1113433A (en) * | 1995-01-06 | 1995-12-20 | 北京农业大学 | Antiparasitic medicine |
-
1997
- 1997-03-27 CN CN97103659A patent/CN1069032C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1069033C (en) * | 1998-11-13 | 2001-08-01 | 王玉万 | Anti-parasite oral spray containing evericin and ivermectin for sheep |
| WO2000074489A1 (en) * | 1999-06-04 | 2000-12-14 | Nufarm Limited | Stable biocidal compositions |
| WO2004043445A1 (en) * | 2002-11-11 | 2004-05-27 | Schering-Plough Ltd. | Topical parasiticide formulations and methods of treatment |
| CN101002560B (en) * | 2006-01-17 | 2010-08-18 | 上海农乐生物制品股份有限公司 | Aqueous emulsion containing methyl amino abamectin benzoate, and its preparing method |
| WO2009060063A1 (en) * | 2007-11-09 | 2009-05-14 | Intervet International B.V. | Anthelmintic combination |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1069032C (en) | 2001-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3884461T2 (en) | Antibiotic polymer composition. | |
| DE69922296T2 (en) | ANTIBACTERILLE COMPOSITION FOR TOPICAL APPLICATION, CONTAINING FAROPENEM | |
| EP1634584A1 (en) | Dimeticone-containing sustained formulation | |
| EP1066029B1 (en) | Peroral active agent suspension | |
| DE60105322T2 (en) | AQUEOUS COMPOSITION CONTAINING AMPHOTERICIN B | |
| DE1083985B (en) | Process for the production of powdery therapeutic preparations which can be converted into stable, aqueous suspensions | |
| CA2161703C (en) | Pour-on formulations containing polymeric material, glycols and glycerides | |
| CN1069032C (en) | Antiparasitic medicine containing avermectin/ivermectin for animals | |
| CN101862294B (en) | Ivermectin suspending agent, preparation method and application thereof | |
| CN1063914C (en) | Plant protection pesticide containing avermectin | |
| CH647675A5 (en) | METHOD FOR PRODUCING MICROCAPSULES CONTAINING ACTIVE PHARMACEUTICAL COMPOUNDS. | |
| CN101444484A (en) | Suspension emulsion of florfenicol, preparation method and application thereof | |
| US20200045969A1 (en) | Fungicidal Composition and Fungicide for Controlling Asparagus Stem Blight | |
| EP1787641A1 (en) | Tazobactam-piperacillin lyophilisate | |
| CN1241404A (en) | Avermectin-or ivermectin-containing slow releasing injecta | |
| CN1989956A (en) | Adapalene gel composition and its preparation | |
| CN105708850A (en) | Invermectin and fenbendazole suspension injection and preparing method thereof | |
| US20030040494A1 (en) | Application of water and organic solvent soluble invermectin for topical and oral use | |
| CN104069266A (en) | Plant essential oil composition for veterinary use | |
| CN1044440C (en) | Animal anti-parasite oral liquor containing avilamycin or envimycin | |
| CN1500492A (en) | Veterinary antiparasite suspension injection | |
| DE3851842T2 (en) | AQUEOUS PREPARATION OF LIPOSOME COMPOSITIONS. | |
| US4894237A (en) | Antiinflammatory pharmaceutical composition endowed with sustained effect for topical use | |
| CN1291646C (en) | Preparation method of pesticide water dispersible soft particles | |
| CN1069033C (en) | Anti-parasite oral spray containing evericin and ivermectin for sheep |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Applicant after: China Agricultural University Applicant before: Wang Yuwan Applicant before: Pan Zhende Applicant before: Dai Xiaoxi Applicant before: You Cunhua |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: WANG YUWAN; PAN ZHENDE; DAI XIAOXI; YOU CUNHUA TO: CHINA AGRICULTURAL UNIVERSITY |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING ZHONGNON DA BIOLOGY TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: CHINA AGRICULTURAL UNIVERSITY Effective date: 20030613 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20030613 Address after: Limited by Share Ltd Beijing agricultural biotechnology in Beijing Haidian District City, Old Summer Palace West Road No. 2 Patentee after: Beijing C.A.U Bio-Technology Co., Ltd. Address before: Room 24, building 2, No. 509 Old Summer Palace West Road, Beijing, Haidian District Patentee before: China Agricultural University |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20010801 Termination date: 20100327 |